Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of therapeutic solutions for physicians and providers to advance patient care in infectious disease. Durata has completed its DISCOVER 1 and DISCOVER 2 global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.
- Dec 3 2013, 8:00 AM EST
Durata Therapeutics Submits Marketing Authorization Application for Dalbavancin
- Nov 26 2013, 4:15 PM EST
Durata Therapeutics Announces FDA's Acceptance for Priority Review of NDA for Dalvance(TM) (dalbavancin hydrochloride)
- Nov 15 2013, 4:00 PM EST
Durata Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference